GlassScriptPhysician profile
Ricardo Martinez
NPI 1285674382
$2,188.83
in general payments reported to CMS, 2019-2025
18 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $135 · 2021: $208 · 2022: $355 · 2023: $153 · 2024: $109 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $338.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.23 | 2021-2022 | |
| Amarin Pharma, INC. | $236.80 | 2019 | |
| Lilly USA, LLC | $194.27 | 2019 | |
| Ucb, INC. | $172.09 | 2022-2025 | Briviact, Rystiggo |
| Biohaven Pharmaceutical Holding Company LTD. | $141.37 | 2022 | |
| Janssen Pharmaceuticals, INC | $140.82 | 2023-2024 | Xarelto |
| Pfizer INC. | $129.23 | 2019-2020 | |
| Exact Sciences Corporation | $114.13 | 2025 | The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $110.50 | 2019 | |
| Sanofi Pasteur INC. | $83.90 | 2019 | |
| Glaxosmithkline, LLC. | $81.79 | 2020-2025 | Shingrix, Arexvy |
| Livanova USA, INC. | $70.73 | 2021 | |
| Octapharma USA, INC. | $36.06 | 2024-2025 | Fibryga, Balfaxar |
| Sumitomo Pharma America, INC. | $31.36 | 2023 | Aptiom |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.98 | 2025 | |
| Sunovion Pharmaceuticals INC. | $20.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.